Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (231-240 of 868) with videos related to

Pageof 87
Sort By:
Biochemical and Biophysical Research Communications|December 3, 2002
The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferationToru Yamaguchi, Mika Yamauchi, Toshitsugu Sugimoto, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell MalignanciesSteven P. Treon, Constantine Mitsiades, Nicholas Mitsiades, et al.
Current Pharmaceutical Design|September 29, 2012
New insights into the treatment of multiple myeloma with histone deacetylase inhibitorsMichele Cea, Antonia Cagnetta, Marco Gobbi, et al.
British Journal of Haematology|October 13, 2015
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomideDeepika S Das, Arghya Ray, Yan Song, et al.
British Journal of Haematology|September 29, 2011
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cellsDharminder Chauhan, Madhavi Bandi, Ajita V Singh, et al.
Blood Cancer Journal|April 2, 2022
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
Blood|December 8, 2009
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita V Singh, Bryan Ciccarelli, et al.
Blood|February 7, 2002
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cellsYu-Tzu Tai, Klaus Podar, Deepak Gupta, et al.
Expert Review of Anticancer Therapy|July 1, 2008
Bortezomib in the front-line treatment of multiple myelomaPaul G Richardson, Constantine Mitsiades, Robert Schlossman, et al.
Blood|July 28, 2012
How I treat plasma cell leukemiaNiels W C J van de Donk, Henk M Lokhorst, Kenneth C Anderson, et al.
Pageof 87

Showing results (231-240 of 868) with videos related to

Sort By:
Pageof 87
Biochemical and Biophysical Research Communications|December 3, 2002
The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferationToru Yamaguchi, Mika Yamauchi, Toshitsugu Sugimoto, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell MalignanciesSteven P. Treon, Constantine Mitsiades, Nicholas Mitsiades, et al.
Current Pharmaceutical Design|September 29, 2012
New insights into the treatment of multiple myeloma with histone deacetylase inhibitorsMichele Cea, Antonia Cagnetta, Marco Gobbi, et al.
British Journal of Haematology|October 13, 2015
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomideDeepika S Das, Arghya Ray, Yan Song, et al.
British Journal of Haematology|September 29, 2011
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cellsDharminder Chauhan, Madhavi Bandi, Ajita V Singh, et al.
Blood Cancer Journal|April 2, 2022
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
Blood|December 8, 2009
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita V Singh, Bryan Ciccarelli, et al.
Blood|February 7, 2002
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cellsYu-Tzu Tai, Klaus Podar, Deepak Gupta, et al.
Expert Review of Anticancer Therapy|July 1, 2008
Bortezomib in the front-line treatment of multiple myelomaPaul G Richardson, Constantine Mitsiades, Robert Schlossman, et al.
Blood|July 28, 2012
How I treat plasma cell leukemiaNiels W C J van de Donk, Henk M Lokhorst, Kenneth C Anderson, et al.
Pageof 87